Cabio Biotech Wuhan Co Ltd (688089) - Total Assets
Based on the latest financial reports, Cabio Biotech Wuhan Co Ltd (688089) holds total assets worth CN¥1.82 Billion CNY (≈ $266.73 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Cabio Biotech Wuhan Co Ltd net assets for net asset value and shareholders' equity analysis.
Cabio Biotech Wuhan Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Cabio Biotech Wuhan Co Ltd's total assets have evolved over time, based on quarterly financial data.
Cabio Biotech Wuhan Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Cabio Biotech Wuhan Co Ltd's total assets of CN¥1.82 Billion consist of 38.9% current assets and 61.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.1% |
| Accounts Receivable | CN¥311.30 Million | 18.5% |
| Inventory | CN¥139.32 Million | 8.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥43.09 Million | 2.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Cabio Biotech Wuhan Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 688089 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cabio Biotech Wuhan Co Ltd's current assets represent 38.9% of total assets in 2024, a decrease from 49.6% in 2013.
- Cash Position: Cash and equivalents constituted 9.1% of total assets in 2024, down from 13.1% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 5.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 18.5% of total assets.
Cabio Biotech Wuhan Co Ltd Competitors by Total Assets
Key competitors of Cabio Biotech Wuhan Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $504.60 Million |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $563.83 Million |
Cabio Biotech Wuhan Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.79 | 6.22 | 21.47 |
| Quick Ratio | 4.44 | 5.01 | 20.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥626.44 Million | CN¥564.27 Million | CN¥1.07 Billion |
Cabio Biotech Wuhan Co Ltd - Advanced Valuation Insights
This section examines the relationship between Cabio Biotech Wuhan Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.00 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | 4.7% |
| Total Assets | CN¥1.69 Billion |
| Market Capitalization | $392.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cabio Biotech Wuhan Co Ltd's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Cabio Biotech Wuhan Co Ltd's assets grew by 4.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Cabio Biotech Wuhan Co Ltd (2013–2024)
The table below shows the annual total assets of Cabio Biotech Wuhan Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.69 Billion ≈ $246.83 Million |
+4.67% |
| 2023-12-31 | CN¥1.61 Billion ≈ $235.81 Million |
+0.04% |
| 2022-12-31 | CN¥1.61 Billion ≈ $235.71 Million |
+11.21% |
| 2021-12-31 | CN¥1.45 Billion ≈ $211.96 Million |
+4.75% |
| 2020-12-31 | CN¥1.38 Billion ≈ $202.35 Million |
+6.55% |
| 2019-12-31 | CN¥1.30 Billion ≈ $189.91 Million |
+123.30% |
| 2018-12-31 | CN¥581.19 Million ≈ $85.05 Million |
+14.78% |
| 2017-12-31 | CN¥506.37 Million ≈ $74.10 Million |
+6.21% |
| 2016-12-31 | CN¥476.78 Million ≈ $69.77 Million |
+8.25% |
| 2015-12-31 | CN¥440.43 Million ≈ $64.45 Million |
-13.20% |
| 2014-12-31 | CN¥507.41 Million ≈ $74.25 Million |
+8.44% |
| 2013-12-31 | CN¥467.92 Million ≈ $68.47 Million |
-- |
About Cabio Biotech Wuhan Co Ltd
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.